Homing of radiolabelled xenogeneic equine peripheral blood-derived MSCs towards a joint lesion in a dog.
Authors: Beerts Charlotte, Pauwelyn Glenn, Depuydt Eva, Xu Yangfeng, Saunders Jimmy H, Peremans Kathelijne, Spaas Jan H
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Osteoarthritis management in dogs remains largely palliative, focusing on pain control rather than disease modification, making mesenchymal stem cell (MSC) therapy an intriguing alternative strategy if efficacy can be demonstrated. Beerts and colleagues administered intravenously 99mTechnetium-labelled equine peripheral blood-derived MSCs to a 9-year-old dog with naturally occurring cranial cruciate ligament rupture, then tracked cellular biodistribution over six hours using full-body scintigraphy imaging. The critical finding was preferential homing of xenogeneic MSCs to the damaged joint, with 40.61% higher radioactive uptake in the affected stifle compared to its healthy contralateral counterpart; the cells also localised to expected organs (liver, spleen, lungs, heart, kidneys) and unexpectedly to a recently injured tail region, with no adverse clinical effects or ectopic tissue formation observed. This case report provides the first in-vivo evidence that equine-derived MSCs—administered intravenously to a different species—actively migrate toward sites of joint pathology, suggesting biological targeting mechanisms may underpin their therapeutic potential rather than random distribution. For equine practitioners considering stem cell therapy in their own patients, these findings validate the biological plausibility of MSC homing to lesions, though larger controlled studies are needed to establish whether this preferential localisation translates to clinically meaningful improvements in lameness and joint healing.
Read the full abstract on PubMed
Practical Takeaways
- •Equine-derived MSCs can successfully navigate to diseased joints when administered intravenously in dogs, suggesting cross-species MSC therapy warrants further investigation for OA treatment
- •MSCs appear to preferentially accumulate at injury sites rather than distributing randomly, supporting their potential as targeted biological therapies for joint disease
- •Safety profile appears favorable with no adverse effects observed in acute period, though long-term safety and therapeutic efficacy data remain limited
Key Findings
- •Xenogeneic equine MSCs successfully homed to the injured joint, showing 40.61% higher uptake in the affected joint compared to the healthy contralateral joint
- •Radiolabelled MSCs distributed to liver, heart, lung, spleen, kidneys, and bladder following intravenous administration
- •MSCs also accumulated at a secondarily injured tail site, demonstrating homing to multiple lesion locations
- •No clinical abnormalities or ectopic tissue formations were detected during the 6-hour follow-up period